Speakers


Check out the mini-curriculum, just click on the Speaker’s name:


International Speakers

ALEJANDRO JUÁREZ


ANDRÉS CERVANTES 
ANDRÉS CERVANTES
Professor Andrés Cervantes is the General Director of the Cancer Area at the Institute of Health Research INCLIVA in Valencia and he is Professor of Medicine at the University of Valencia. He completed his training in Medical Oncology at the University Hospital in Valencia. After completing his clinical training he got a research fellowship for two years at the Free University Hospital in Amsterdam, where he obtained his PhD degree with a work on multidrug resistance in the Cellular Pharmacology Lab of this institution.

Professor Cervantes serves as Head of Section in Medical Oncology at the Dept. of Haematology and Medical Oncology at the University Hospital in Valencia. His main areas of research and clinical interest are gastrointestinal and gynaecologic malignancies as well as phase I trials and new drug development. He is the author of many research articles and educational papers published in peer-reviewed journals. He is also the Editor of Cancer Treatment Reviews and Clinical and Translational Oncology. Since January 2014, he is serving Annals of Oncology, the ESMO flagship journal, as Associate Editor for the gastrointestinal malignancies area. He is ESMO‘s Educational Committee Chair.



ARNDT VOGEL 
ARNDT VOGEL
Arndt Vogel, MD, is managing senior physician and assistant professor in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School (Director Prof. Dr. M.P. Manns). He is responsible for patients with gastrointestinal tumors and part of the endoscopy team. He is leading a research group interested in the pathogenesis and treatment of GI-cancer.

Arndt Vogel studied Medicine and graduated in Medicine at the University of Göttingen in 1998. He received his medical training in Internal Medicine and Gastroenterology at Hannover Medical School, Germany. From 2002 to 2004 he served as a Postdoctoral Fellow at Oregon Health & Science University, Portland, Oregon.

Arndt Vogel is a clinical investigator in oncology since 2006 and has served as Principal Investigator on several phase I - III trials and has conducted several investigator-initiated trial. He is a member of societies including the American Society of Clinical Oncology, the European Society for Medical Oncology, and the European Association for the Study of the Liver. Arndt Vogel has responsibilities in the establishment of the national guideline and is the coordinator of the ESMO clinical practice guideline 2018 on the management of hepatocellular carcinoma.

Since 2004, Arndt Vogel is head of a research group that is focused on molecular aspects of hepatocellular carcinoma. Several foundations and agencies, among other the Deutsche Krebshilfe and Deutsche Forschungsgemeinschaft, fund his basic research. Arndt Vogel is a Reviewer or Editor for many top-tier scientific journals and the author or coauthor of articles published in peer-reviewed journals including Cancer Cell, Gastroenterology, and Hepatology, as well as numerous book chapters.



EVANDRO DE AZAMBUJA 
EVANDRO DE AZAMBUJA
Evandro de Azambuja, MD, PhD, is the Head of the Medical Support Team (Academic Promoting Team) located at the Jules Bordet Institute in Brussels, Belgium.

Dr de Azambuja earned his first PhD from the Federal University of Rio Grande do Sul, Porto Alegre, Brazil, in May 2007 and his second PhD from the Université Libre de Bruxelles (U.L.B) in December 2015.

His principal interest in oncology is breast cancer, especially in the adjuvant/neoadjuvant settings. He is deeply involved in the conduct of large phase III trials in breast cancer such as HERA (adjuvant trastuzumab), ALTTO (trastuzumab and/or lapatinib) and APHINITY (trastuzumab with or without pertuzumab) and – in the neoadjuvant setting – the LORELEI trial which tests the efficacy of PI3K inhibition. He is also greatly engaged in studies concerning cancer toxicity of new drugs in oncology as well as in long-term follow-up of patients enrolled in clinical trials with focus in cardiotoxicity. Within the latter context, he was a co-author of guidelines on treatment-related cardiac toxicity by the European Society of Medical Oncology (ESMO) and the European Society of Cardiology (ESC). He was past Chair of the survivorship group of the Belgian Society of Medical Oncology (BSMO).

Dr. de Azambuja was a member of the ESMO Young Oncologists Committee (YOC), a faculty member of the ESMO Leaders Generation Programme launched in 2016 and he was also appointed as a Breast Faculty Member of ESMO in 2017 and a Board Member of the Belgian Society of Medical Oncology (BSMO) since 2015.

He is currently Fellowship & Award Committee Chair (2018-2019) of ESMO and also serves as member of its Executive Board.

Dr. de Azambuja is also a member of the American Society of Clinical Oncology (ASCO) and the Belgian Society of Medical Oncology (BSMO). He is actively involved in editorial boards of the Journal of Clinical Oncology (JCO), “ESMO Open – Cancer Horizons”, and ESMO Perspective.

He has (co)-authored approximately 150 peer-reviewed articles and 9 book chapters.

He has been a member of Education and Scientific Committees of the ESMO, EBCC and ECCO meetings.



FORTUNATO CIARDIELLO 
FORTUNATO CIARDIELLO
Fortunato Ciardiello was born in Naples, on August 4, 1960.

Fortunato Ciardiello, MD, PhD is currently Full Professor of Medical Oncology, Head of the Laboratory of Experimental Therapeutics, Head of the Division of Medical Oncology, Director of the Dipartmento Medico-Chirurgico di Internistica Clinica e Sperimentale, Member of the Academic Senate, Seconda Università di Napoli in Naples, Italy. He is currently also the Director of the Specialty Programme in Medical Oncology.

Professor Ciardiello received his MD degree, his speciality degree in Medical Oncology, and his PhD degree in Molecular Biology and Pathology from the University of Naples, Italy. He also trained in translational cancer research for almost 5 years at the National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. Professor Ciardiello received the G Venosta Award from the Italian Foundation for Cancer Research (FIRC) in November 2000 for research on novel therapeutic strategies in cancer.

Professor Ciardiello’s research interests include the role of growth factors and their specific receptors in neoplastic transformation and the development of novel therapeutic strategies targeting growth factor receptor signalling. He has published 315 research articles, as listed in PubMed, within these specific areas of interest. Professor Ciardiello’s cumulative impact factor is approximately 1400 and his H index is 76.

His major scientific achievements can be summarised as follows:

Identification of transforming growth factor alpha (TGF alpha) as a major ligand for the epidermal growth factor receptor (EGFR) and its role in the development and progression of human epithelial cancer (in particular, breast, colorectal and lung cancer).
Identification of the transforming properties of CRIPTO, an EGF-related growth factor in human cancer.
Identification of the role of cAMP-dependent protein kinase (PKA) as a down-stream signal in the pathway of activated EGFR in human cancer.
Study of selective anti-EGFR agents in preclinical models for the development of novel drugs that now are on the market (cetuximab, gefitinib) alone and/or in combination with conventional cytotoxics, with radiation or with other molecular targeted agents.
Study of the molecular and cellular mechanisms of acquired resistance of cancer cells to the therapeutic effects of anti-EGFR drugs.
Furthermore, he has been essential participant or the principal investigator to the development, design, conduction and interpretration of several phase I, phase II and phase III key clinical trials which have been conducted in metastatic colorectal and lung cancers (for drugs such gefitinib, erlotinib, cetuximab, sorafenib, regorafenib, vandetanib, MEK inhibitors).
Currently, Professor Ciardiello leads a team of medical oncologists who are dedicated in a broad translational research programme to the preclinical development and to the transfer to patients of novel and more effective molecular targeted approaches for the medical treatment of colorectal and non-small cell lung cancer.

He is an active member of several international scientific societies, including the European Society for Medical Oncology (ESMO), the American Association of Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO).

Professor Ciardiello is ESMO Past-President and an ESMO Executive Board Member; he served as ESMO President 2016-2017.

Professor Ciardiello also serves on the editorial boards of Clinical Cancer Research, Annals of Oncology, International Journal of Oncology; Targeted Oncology, and Oncology Reports.



JEAN-PASCAL MACHIELS 
JEAN-PASCAL MACHIELS
Jean-Pascal Machiels, MD, PhD, is Head of the Department of Medical Oncology at the Cliniques Universitaires Sain-Luc, Brussels, Belgium. He is also a member of the Directory Board of the Oncology Center at Cliniques Universitaires St-Luc since 2005.

Dr. Machiels graduated from the Johns Hopkins School of Medicine, Baltimore USA (Fellow in Medical Oncology, 1998-2000), and obtained his MD degree in 1993 and PhD in 2001 from the Université catholique de Louvain, Brussels, Belgium where he is currently professor (clinical).

His main interests cover the fields of head and neck cancer, clinical and translational research, and early clinical trials (phase 1). He is Section Editor (head and neck cancer) for the European Journal of Cancer (EJC).

Dr. Machiels has published more than one hundred papers reporting on clinical trials and translational research.

In 2000, Dr. Machiels won the ‘Translational Research Award, First Prize‘, Johns Hopkins Oncology Center, Baltimore, USA, and in 2002 the AMGEN Award from the Belgian Society of Medical Oncology.

Dr. Machiels was a member of the ESMO Head and Neck Cancer Faculty Group from 2012 to 2016. Since 2017, he has been a member of the ESMO Educational Committee, coordinator of the ESMO Head and Neck Cancer Faculty Group and a Deputy Subject Editor of the ESMO Guidelines Committee.



JORGE GALLARDO


JOSEP TABERNERO 
JOSEP TABERNERO
Josep Tabernero holds MD and PhD degrees from the Universitat Autònoma de Barcelona, Spain. He is currently Head of the Medical Oncology Department at the Vall d’Hebron Barcelona Hospital Campus, Director of the Vall d’Hebron Institute of Oncology (VHIO), and leads the Research Innovation of Catalonian Cancer Centers Network.

He also directs VHIO´s Gastrointestinal and Endocrine Tumors Group, the Research Unit for Molecular Therapy of Cancer (UITM) – “la Caixa”, and is Principal Investigator of several Phase I pharmacodynamic studies and translational projects with molecular targeted therapies, with particular emphasis on EGFR-family inhibitors and IGFR-PI3K-Akt-mTOR pathway inhibitors, as well as phase II and III studies with novel chemotherapeutics.

Based on the idea that each tumor has an independent genetic identity, his group aims at potentiating molecular therapies targeting specific oncoproteins and accelerating more effective personalized cancer medicines for patients displaying genetic lesions or pathway disregulation. One of his team´s main objectives is to establish novel predictive markers of response to anti-cancer therapies and identify markers of primary resistance (de novo) and secondary treatment.

At preclinical level, in collaboration with VHIO´s cancer researchers and physician-scientists, he develops new xenograft models with explant tumors from patients (“xenopatients”) in mice in order to mimic the patient’s disease and study tumor development in optimal research models. He also leads research into the study of circulating biomarkers (detection and genotyping of circulating free DNA), and is dedicated to advancing the immuno-oncology field through a large portfolio of trials with some of the most promising targets in immune checkpoints and cytokines. By paring immune therapeutics with oncogenomics, his team seeks to render anti-cancer therapies more precise.

Dr. Tabernero serves on the Editorial Boards of various top tier journals including Annals of Oncology, ESMO Open, Cancer Discovery and Clinical Cancer Research. He has (co) authored approximately 350 peer-reviewed papers.

He is currently ESMO President (2018 – 2019) of the European Society for Medical Oncology (ESMO) and an Executive Board Member. He is also member of the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO), and has been appointed as member of several Educational and Scientific Committees of ESMO, ECCO, ASCO, AACR, AACR/NCI/EORTC, ASCO Gastrointestinal, and WCGIC meetings.



KARIN JORDAN 
KARIN JORDAN
Professor Karin Jordan graduated from Martin Luther University of Halle-Wittenberg, Germany. Following a number of posts at the University Hospital Halle and Bernward Hospital, Hildesheim, she was appointed as a specialist in Internal Medicine and Haematology and Oncology at the University of Halle-Wittenberg.

Since 2017 she is the leading senior physician of the Department of Haematology and Oncology at the University Hospital in Heidelberg, Germany. She was the vice executive director of the ethics committee at the University of Halle from 2009-2015.

Professor Jordan has served as a board member of MASCC/ESMO Antiemetic Guideline Consensus Panel in 2009 and 2015, and is in the ASCO antiemetic guideline panel. She holds the co-chair of Supportive Care study group within the German Society of Medical Oncology (AIO) and is the associate chair of the German Association of Supportive Care in Oncology, Rehabilitation and Social Medicine (ASORS).

Professor Jordan was also a member of the ESMO Young Oncologist Committee. Since 2013 she is the coordinator of the S3 Guidelines on Supportive Care within the Oncology Guideline Programme of the German Cancer Society and in 2014 became an associate editor of Annals of Oncology. Since 2017 she is the ESMO Faculty coordinator for Supportive & Palliative Care and also the ESMO Clinical Practice Guidelines subject editor for the supportive care section.

Professor Jordan has authored and co-authored more than 120 publications and her major area of interest is supportive care with a special focus on antiemetic treatment of chemotherapy-induced nausea and vomiting and side effects of new drugs.



MARIA TERESA BOURLON
NORA SOBREVILLA
OSCAR ARRIETA
PAOLO ASCIERTO 
PAOLO ASCIERTO
Paolo A. Ascierto obtained his medical degree from the University of Naples, Italy, the institution where he subsequently earned his Board Certification in Oncology. He went on to serve consecutive positions at the National Tumour Institute “Fondazione G. Pascale”, in Naples, as a postdoctoral fellow and then as Vice Director of the Department of Clinical Immunology. Professor Ascierto is currently Director of the Unit of Melanoma, Cancer Immunotherapy and Innovative therapy at that same institution. He is an active Scientific Reviewer for several international journals, including, JCO, Lancet Oncology, and Clinical Cancer Research, as well as being the Editor-in-Chief of the Combination Strategies section of the Journal of Translational Medicine and Chief Section Editor of Expert Reviews of Immunology Vaccines and Informatics. As a result of Professor Ascierto’s experience and expertise, he has been a valued invited speaker at more than 350 national and international meetings. Furthermore, he is an active member of the Italian Society of Medical Oncology (AIOM), American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO), European Organization for Research and Treatment of Cancer (EORTC) and Society of Immuno Therapy of Cancer (SITC). Professor Ascierto has presided as Principal Investigator on over 50 clinical trials and he is the author of numerous publications in peer-reviewed journals. Such journals include: The New England Journal of Medicine, Lancet Oncology, Journal of Clinical Oncology, and Clinical Cancer Research, among others. Primarily, his major research interests are the genetics and proteomics of melanoma, the assessment of molecular markers for tumour progression in melanoma, management of targeted therapies for melanoma, vaccination treatments and immunotherapy of cancer, biochemical and immunological monitoring, and combination approaches for the cancer treatment.

RONALD DE WIT 
RONALD DE WIT
Professor Ronald de Wit is Medical Oncologist, senior staff member and full professor at the Erasmus MC Cancer Institute. He earned his medical degree at the University of Amsterdam and specialized in Internal Medicine and Medical Oncology (1982-1990). Prof de Wit is member of a wide range of professional societies and committees and serves as Faculty and Program Committee Member of the American Society of Clinical Oncology (ASCO) and the European Society of Medical Oncology (ESMO) 1999-ongoing. He is track chair for Genito-Urinary Cancer ESMO-Asia 2018. His research focus is Genito-Urinary Oncology. He is former chairman of the EORTC-Genitourinary Group Chemotherapy Subcommittee and initiated and led randomized studies in testicular cancer, renal and bladder cancer. He co-chaired phase 3 registration trials, ranging from docetaxel (TAX 327), and AR targeted agents, to checkpoint inhibition (PD-1) trials in bladder cancer. He is involved in a wide variety of ongoing clinical studies and serves on Industry Advisory Board Committees, as well as Data Monitoring Committees. Prof de Wit is collaborating with the Dpts of Urology and Translational Pathology in preclinical and clinical translational research. In 2011 he launched the Dutch Uro Oncology Study Group (www.stichtingduos.nl) creating a collaborative network of 25 academic and supraregional hospitals in the Netherlands and is Chairman of the Group. His publications include over 280 papers and book chapters.

SOLANGE PETERS 
SOLANGE PETERS
Solange Peters, MD-PhD, achieved her MD from the Medical School at the University of Lausanne in 1998, following this she attended the Microbiology Institute at the University of Lausanne until 2002, concluding with a MD-PhD thesis on new HIV drug-resistance mechanisms. From 2002-2006, Prof. Peters did her residency in Internal Medicine, followed by a Fellowship at the Multidisciplinary Oncology Centre, both at the University Hospital of Lausanne. In September 2006, she sat the ESMO Examination in Oncology and was awarded the ESMO Best European Exam result. This was shortly followed by the SSMO (Swiss Society of Medical Oncology) oral exam November 2006. In 2013, Prof. Peters received the title of Lausanne University Private Docent (PD-MER) and was appointed Professor and Head of Medical Oncology at the Faculty of Biology and Medicine in Lausanne successively in 2015 and 2016. Prof. Peters is currently in charge of teaching and patient care in the area of medical oncology and thoracic malignancies at the Department of Oncology of Lausanne University, where she is building a translational programme in collaboration with the molecular oncology laboratory directed by Prof. D. Hanahan and Prof. E. Meylan in Swiss Federal Institute of Technology in Lausanne and the Ludwig Institute. Prof. Peters’ main field of interest is new biomarker discovery and validation in preclinical and clinical settings. She is also strongly involved and interested in multimodality trial building for locally-advanced NSCLC as well as clinical and translational cancer immunotherapy. Her current research projects as a chair are focused on multimodality curative-intent treatment of stage III NSCLC, combined immunotherapy for the treatment of NSCLC, SCLC, thymic malignancies and mesothelioma, denosumab in advanced NSCLC, ALK, RET, EGFR as well HER2 inhibitors. She acts as the local PI of lung trials opened in Lausanne Cancer Centre, focused on phase I, predictive biomarkers and NSCLC immunotherapy. In addition, she is a co-PI of several other trials. She is co-chair of Swiss Lung Cancer Research group, and responsible for trials organisation and coordination, as well as related databases for the ETOP (European Thoracic Oncology Platform) Lungscape project database (member of the steering committee), where she is responsible for communication, scientific coordinaton and member of the Foundation Council. Prof. Solange Peters is an active member of the educational programme within ESMO. Prof. Peters is currently President-elect (2018 – 2019) of the European Society for Medical Oncology‘s (ESMO), serves as member of its Executive Board and also she is Chair of the Women for Oncology Committee and ESMO Faculty for Lung and Other Thoracic Cancers. She was member of the ESMO E-Learning and CME Committee and elected ESMO Swiss National Representative. She is also subject editor for the ESMO Guidelines Working Group. She was the scientific chair of ELCC 2016 and acts as chair of ESMO 2018 annual congress in Munich. She is in parallel active in IASLC where she also acts as a Board Member. She is a member of AACR (American Association for Cancer Research) and EORTC (European Organisation for Research and Treatment of Cancer). Of national organisations, Prof. Peters is vice President of SAMO (Swiss Academy for Multidisciplinary Oncology), member of SAKK (Swiss Group for Clinical Cancer Research), FMH (Association of Swiss Physicians) and ASMAC/VSAO (Association of Swiss Interns and Residents) and was the president of FOROME (Association Romande pour la formation continue en oncologie médicale) for 5 years. Prof. Peters has authored numerous peer-reviewed manuscripts and book chapters, served as the associate editor of ‘Lung Cancer’ and became Deputy Editor of the ‘Journal of Thoracic Oncology’ (JTO), the official journal of IASLC, in 2013. She was Editor in Chief of Cancer Treatment Communications. In addition, she acts as Associate Editor for ‘Frontiers in Pharmacology of Anti-Cancer Drugs’ and Review Editor for ‘Frontiers in Thoracic Oncology’. She is the author of numerous articles in peer-reviewed publications as well as book chapters and abstracts and the Co-Editor of the book "Perspectives in Thoracic Oncology" (UNI-MED), the book series ‘Progress in Tumor Research’ (Karger) as well as new therapeutic strategies in lung cancers (Springer).

SUSANA BANERJEE 
SUSANA BANERJEE
Dr Susana Banerjee (MBBS MA MRCP PhD) is a Consultant Medical Oncologist and Research Lead for the Gynaecology Unit at the Royal Marsden, London, UK. She is a Team Leader (Associate Honorary Faculty) in Gynaecological Cancers at the Institute of Cancer Research. Dr Banerjee specialises in ovarian cancer and the systemic treatment of endometrial and cervical cancers. Dr. Banerjee graduated with a 1st class from St. John‘s College, University of Cambridge and completed her medical training at Royal Free Medical School where she was a University of London Gold Medal Finalist. Dr Banerjee was awarded an Avon Breast Cancer Crusade Clinical Fellowship for laboratory research and gained a PhD from the Institute of Cancer Research, University of London. She was awarded the San Antonio Breast Cancer Symposium Novartis Oncology Basic Science Award for her research in 2007. Other prizes include the Association of Cancer Physicians McElwain Prize and the Sir Antony Driver Prize. She was also ‘highly commended‘ for the Pfizer British Oncology Association Young Investigator Award. She completed specialist training at The Royal Marsden and was appointed a Consultant in 2011. Dr Banerjee serves on several national and international specialist groups including the National Cancer Research Institute (NCRI) Gynaecological Cancers Clinical Studies Group, European Organization for Research and Treatment of Cancer (EORTC) Executive Steering Committee for Gynaecological Cancers, NCRI ovarian and cervical cancer subgroups. She also served on the ESGO (European Society of Gynaecological Oncology) Faculty in 2015. Dr Susana Banerjee was an active member of the ESMO Young Oncologists‘ Committee (YOC) from 2010-2016. She led the ESMO YOC Burnout Survey- the largest survey in Europe presented in 2014. She served on the ESMO Nominating Committee 2014-2015 and is currently a member of the ESMO Women for Oncology Committee. Dr Banerjee was selected to be part of the first Leaders Generation Programme in 2016. Susana is involved in a number of ESMO-related educational activities including being Co-Chair of the ESMO Medical Students Course (2015 and 2016), Track Chair (Young Oncologist) for the European Cancer Congress in 2015 and a member of the OncologyPro Working Group. She is an author of the ESMO/ASCO Global Curriculum in Medical Oncology, ESMO-ESGO-ESTRO Consensus on Endometrial Cancer and Co-Editor of the ESMO Handbook of Translational Research. She is on the Gynaecological Cancers sub-committee for the ESMO Congress 2017 (in partnership with EACR) and the Track Chair for Gynaecological Cancers for the ESMO Congress 2018. She joined the ESMO Executive Board in 2017. Dr Banerjee is actively involved in clinical trials and translational research. Her research interests include individualisation of patient treatment and targeted therapies in gynaecological cancers. Dr Banerjee is UK Chief Investigator and principal investigator at the Royal Marsden for multiple national and international clinical trials. She is on the Advisory Board for Nature Reviews Clinical Oncology journal and Editorial Boards of Cancer Treatment Reviews and ESMO Open.

YANIN CHÁVARRI GUERRA



National Speakers

ANDRÉIA CRISTINA MELO 
ANDRÉIA CRISTINA MELO
Graduação em Medicina pela Universidade Federal de Minas Gerais. Fez sua formação em Oncologia Clínica no Instituto Nacional de Câncer (INCA). Doutora em Oncologia pelo INCA (2015). Atualmente é chefe da Divisão de Ensaios Clínicos e Desenvolvimento de Fármacos do INCA, Oncologista da Oncologia D’or e presidente da SBOC regional Rio de Janeiro


ANGELICA NOGUEIRA RODRIGUES 
ANGELICA NOGUEIRA RODRIGUES
Pós-doutorado MGH/Harvard University Professora e pesquisadora UFMG Presidente do Grupo Brasileiro de Tumores Ginecológicos, EVA. Diretora Técnica DOM Oncologia.


FELIPE SANTA ROSA ROITBERG 
FELIPE SANTA ROSA ROITBERG
Médico Titular Centro de Oncologia Hospital Sírio Libanês Médico Assistente do ICESP/FMUSP - Grupo de Tumores Torácicos e de Cabeça e Pescoço Médico Assistente do Departamento de Emergência da Santa Casa de Misericórdia de São Paulo Representante no Comitê de Oncologia da Santa Casa de Misericórdia de São Paulo


LUÍSA LINA VILLA 
LUÍSA LINA VILLA
Luisa Villa é bióloga, PhD em Bioquimica e Biologia Molecular pela USP. Atualmente é Professora Associada do Departamento de Radiologia e Oncologia da Faculdade de Medicina da USP, aonde dirige os laboratórios de Biologia Molecular e de Inovação em Câncer do Instituo do Câncer do Estado de São Paulo-ICESP. Coordenada o Instituto Nacional de Ciência e Tecnologia do HPV (Instituto do HPV). É membro da Academia Brasileira de Ciências.


PAULO MARCELO GEHM HOFF 
PAULO MARCELO GEHM HOFF
- Médico formado pela Universidade de Brasília (1991); - Doutorado e Livre docência em Oncologia pela Faculdade de Medicina da Universidade de São Paulo, onde é professor titular; - Fellowship em Hematologia e Oncologia no MD Anderson Cancer Center;


RAFAEL ARON SCHMERLING 
RAFAEL ARON SCHMERLING
Oncologista Clínico do Hospital São Jose


RICARDO CAPONERO 
RICARDO CAPONERO
Oncologista Clínico Coordenador do Centro Avançado de Terapia de Suporte e Medicina Integrativa do Hospital Alemão Oswaldo Cruz Membro do corpo docente da ESMO para cuidados paliativos 2017-2018


RODRIGO RAMELLA MUNHOZ 
RODRIGO RAMELLA MUNHOZ
Médico Oncologista especialista em tumores cutâneos e sarcomas do Hospital Sírio Libanês e Instituto do Câncer do Estado de São Paulo


SÉRGIO SIMON 
SÉRGIO SIMON
Sergio Daniel Simon CRM 19865 • Formado pela Faculdade de Medicina da Universidade de São Paulo FMUSP (1973) • Residência Médica em Medicina Interna pelo Mount Sinai Medical Center - Miami Beach (1977) • Fellow em Hematologia, Rutgers University, New Jersey (1979) • Fellow em Oncologia Clínica pelo Memorial Sloan Kettering Cancer Center - New York (1980). • Doutorado pela Faculdade de Medicina da Universidade de São Paulo FMUSP (2003) • Membro da ASCO, ESMO. • Oncologista Clínico e sócio fundador do CPO; Diretor Presidente e fundador do GBECAM • Presidente da SBOC




Event Venue

Renaissance São Paulo Hotel - Centro de eventos

Adress: Alameda Santos, 2233 - Cerqueira César
São Paulo – SP - Brazil
Zip Code: 01419-002

Promoted By
Management

Travel Agency

Platinum Sponsorship